Publications
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Lenalidomide in the first and additional lines of therapy for multiple myeloma2012 | First Faculty of Medicine
- An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation2011 | First Faculty of Medicine
- Malignant masquerade syndromes2009 | First Faculty of Medicine, Third Faculty of Medicine
- Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoetinm production2003 | First Faculty of Medicine
- Results of autologous stem cell transplantation for AL amyloidosis in one Czech centerPublication without faculty affiliation
- Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis2023 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Standardized 18F-FDG PET/CT in patients with myeloma: joint recommendation of Czech Myeloma Group and Czech Society of Nuclear Medicine2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Standardization of PET/CT in patients with multiple myeloma – Joint recommendation of The Czech Myeloma Group and The Czech Society of Nuclear Medicine2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
Loading network view...